1
|
Li Y, He C, Liu R, Xiao Z, Sun B. Stem cells therapy for diabetes: from past to future. Cytotherapy 2023; 25:1125-1138. [PMID: 37256240 DOI: 10.1016/j.jcyt.2023.04.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Revised: 04/05/2023] [Accepted: 04/24/2023] [Indexed: 06/01/2023]
Abstract
Diabetes mellitus is a chronic disease of carbohydrate metabolism characterized by uncontrolled hyperglycemia due to the body's impaired ability to produce or respond to insulin. Oral or injectable exogenous insulin and its analogs cannot mimic endogenous insulin secreted by healthy individuals, and pancreatic and islet transplants face a severe shortage of sources and transplant complications, all of which limit the widespread use of traditional strategies in diabetes treatment. We are now in the era of stem cells and their potential in ameliorating human disease. At the same time, the rapid development of gene editing and cell-encapsulation technologies has added to the wings of stem cell therapy. However, there are still many unanswered questions before stem cell therapy can be applied clinically to patients with diabetes. In this review, we discuss the progress of strategies to obtain insulin-producing cells from different types of stem cells, the application of gene editing in stem cell therapy for diabetes, as well as summarize the current advanced cell encapsulation technologies in diabetes therapy and look forward to the future development of stem cell therapy in diabetes.
Collapse
Affiliation(s)
- Yumin Li
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China
| | - Cong He
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China; Department of Hepatobiliary Surgery, Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School, Nanjing, China
| | - Rui Liu
- Department of Genetic Engineering, College of Natural Science, University of Suwon, Kyunggi-Do, Republic of Korea
| | - Zhongdang Xiao
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
| | - Bo Sun
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
| |
Collapse
|
2
|
Sensing and Stimulation Applications of Carbon Nanomaterials in Implantable Brain-Computer Interface. Int J Mol Sci 2023; 24:ijms24065182. [PMID: 36982255 PMCID: PMC10048878 DOI: 10.3390/ijms24065182] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2022] [Revised: 02/23/2023] [Accepted: 02/28/2023] [Indexed: 03/11/2023] Open
Abstract
Implantable brain–computer interfaces (BCIs) are crucial tools for translating basic neuroscience concepts into clinical disease diagnosis and therapy. Among the various components of the technological chain that increases the sensing and stimulation functions of implanted BCI, the interface materials play a critical role. Carbon nanomaterials, with their superior electrical, structural, chemical, and biological capabilities, have become increasingly popular in this field. They have contributed significantly to advancing BCIs by improving the sensor signal quality of electrical and chemical signals, enhancing the impedance and stability of stimulating electrodes, and precisely modulating neural function or inhibiting inflammatory responses through drug release. This comprehensive review provides an overview of carbon nanomaterials’ contributions to the field of BCI and discusses their potential applications. The topic is broadened to include the use of such materials in the field of bioelectronic interfaces, as well as the potential challenges that may arise in future implantable BCI research and development. By exploring these issues, this review aims to provide insight into the exciting developments and opportunities that lie ahead in this rapidly evolving field.
Collapse
|
3
|
Di Trani N, Racca N, Demarchi D, Grattoni A. Comprehensive Analysis of Electrostatic Gating in Nanofluidic Systems. ACS APPLIED MATERIALS & INTERFACES 2022; 14:35400-35408. [PMID: 35905377 DOI: 10.1021/acsami.2c08809] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Molecular transport in nanofluidic systems exhibits properties that are unique to the nanoscale. Here, the electrostatic and steric interactions between particle and surfaces become dominant in determining particle transport. At the solid-liquid interface of charged surfaces an electric double layer (EDL) forms due to electrostatic interactions between surfaces and charged particles. In these systems, tunable charge-selective nanochannels can be generated by manipulating electrostatic gating via co-ions exclusion and counterions enrichment of the EDL at the solid-liquid interface. In this context, electrostatic gating has been used to modulate the selectivity of nanofluidic membranes for drug delivery, nanofluidic transistors, and FlowFET, among other applications. While an extensive body of literature investigating nanofluidic systems exists, there is a lack of a comprehensive analysis accounting for all major parameters involved in these systems. Here we performed an all-encompassing modeling investigation corroborated by experimental analysis to assess the influence of nanochannel size, electrolyte properties, surface chemistry, gate voltage, dielectric properties, and molecular charge and size on the exclusion and enrichment of charged analytes in nanochannels. We found that the leakage current in electrostatic gating, often overlooked, plays a dominant role in molecular exclusion. Importantly, by independently considering all ionic species, we found that counterions compete for EDL formation at the surface proximity, resulting in concentration distributions that are nearly impossible to predict with analytical models. Achieving a deeper understanding of these nanofluidic phenomena will help the development of innovative miniaturized systems for both medical and industrial applications.
Collapse
Affiliation(s)
- Nicola Di Trani
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, United States
| | - Nevio Racca
- Department of Electronics and Telecommunications, Polytechnic of Turin, 10129 Turin, Italy
| | - Danilo Demarchi
- Department of Electronics and Telecommunications, Polytechnic of Turin, 10129 Turin, Italy
| | - Alessandro Grattoni
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, United States
- Department of Surgery, Houston Methodist Research Institute, Houston, Texas 77030, United States
- Department of Radiation Oncology, Houston Methodist Research Institute, Houston, Texas 77030, United States
| |
Collapse
|
4
|
Strand N, J M, Tieppo Francio V, M M, Turkiewicz M, El Helou A, M M, S C, N S, J P, C W. Advances in Pain Medicine: a Review of New Technologies. Curr Pain Headache Rep 2022; 26:605-616. [PMID: 35904729 PMCID: PMC9334973 DOI: 10.1007/s11916-022-01062-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/01/2022] [Indexed: 11/25/2022]
Abstract
PURPOSE OF REVIEW This narrative review highlights the interventional musculoskeletal techniques that have evolved in recent years. RECENT FINDINGS The recent progress in pain medicine technologies presented here represents the ideal treatment of the pain patient which is to provide personalized care. Advances in pain physiology research and pain management technologies support each other concurrently. As new technologies give rise to new perspectives and understanding of pain, new research inspires the development of new technologies.
Collapse
Affiliation(s)
- Natalie Strand
- Department of Anesthesiology, Division of Pain Medicine, Mayo Clinic, Phoenix, AZ, USA.
- NorthShore University HealthSystem, Evanston, IL, USA.
- University of Chicago Medicine, Chicago, IL, USA.
| | - Maloney J
- Department of Anesthesiology, Division of Pain Medicine, Mayo Clinic, Phoenix, AZ, USA
| | - Vinicius Tieppo Francio
- Department of Rehabilitation Medicine, The University of Kansas Medical Center (KUMC), 3901 Rainbow Blvd. MS1046, Kansas City, KS, 66160, USA
| | - Murphy M
- Department of Rehabilitation Medicine, The University of Kansas Medical Center (KUMC), 3901 Rainbow Blvd. MS1046, Kansas City, KS, 66160, USA
| | | | - Antonios El Helou
- Department of Neurosurgery, The Moncton Hospital, Moncton, NB, Canada
| | - Maita M
- Department of Anesthesiology, Division of Pain Medicine, Mayo Clinic, Phoenix, AZ, USA
| | - Covington S
- Department of Anesthesiology, Division of Pain Medicine, Mayo Clinic, Phoenix, AZ, USA
| | - Singh N
- OrthoAlabama Spine and Sports, Birmingham, AL, USA
| | - Peck J
- Performing Arts Medicine Department, Shenandoah University, Winchester, VA, USA
| | - Wie C
- Department of Anesthesiology, Division of Pain Medicine, Mayo Clinic, Phoenix, AZ, USA
| |
Collapse
|
5
|
Sharma R, Geranpayehvaghei M, Ejeian F, Razmjou A, Asadnia M. Recent advances in polymeric nanostructured ion selective membranes for biomedical applications. Talanta 2021; 235:122815. [PMID: 34517671 DOI: 10.1016/j.talanta.2021.122815] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Revised: 08/13/2021] [Accepted: 08/18/2021] [Indexed: 12/30/2022]
Abstract
Nano structured ion-selective membranes (ISMs) are very attractive materials for a wide range of sensing and ion separation applications. The present review focuses on the design principles of various ISMs; nanostructured and ionophore/ion acceptor doped ISMs, and their use in biomedical engineering. Applications of ISMs in the biomedical field have been well-known for more than half a century in potentiometric analysis of biological fluids and pharmaceutical products. However, the emergence of nanotechnology and sophisticated sensing methods assisted in miniaturising ion-selective electrodes to needle-like sensors that can be designed in the form of implantable or wearable devices (smartwatch, tattoo, sweatband, fabric patch) for health monitoring. This article provides a critical review of recent advances in miniaturization, sensing and construction of new devices over last decade (2011-2021). The designing of tunable ISM with biomimetic artificial ion channels offered intensive opportunities and innovative clinical analysis applications, including precise biosensing, controlled drug delivery and early disease diagnosis. This paper will also address the future perspective on potential applications and challenges in the widespread use of ISM for clinical use. Finally, this review details some recommendations and future directions to improve the accuracy and robustness of ISMs for biomedical applications.
Collapse
Affiliation(s)
- Rajni Sharma
- School of Engineering, Macquarie University, Sydney, NSW, 2109, Australia
| | - Marzieh Geranpayehvaghei
- School of Engineering, Macquarie University, Sydney, NSW, 2109, Australia; Department of Nanobiotechnology, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, 14115-175, Iran
| | - Fatemeh Ejeian
- Department of Animal Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran; Department of Biotechnology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, 73441-81746, Iran
| | - Amir Razmjou
- School of Engineering, Macquarie University, Sydney, NSW, 2109, Australia; Department of Biotechnology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, 73441-81746, Iran; Centre for Technology in Water and Wastewater, University of Technology Sydney, New South Wales, Australia; UNESCO Center for Membrane Technology, School of Chemical Engineering, University of New South Wales, Sydney, NSW, 2052, Australia
| | - Mohsen Asadnia
- School of Engineering, Macquarie University, Sydney, NSW, 2109, Australia.
| |
Collapse
|
6
|
Silvestri A, Di Trani N, Canavese G, Motto Ros P, Iannucci L, Grassini S, Wang Y, Liu X, Demarchi D, Grattoni A. Silicon Carbide-Gated Nanofluidic Membrane for Active Control of Electrokinetic Ionic Transport. MEMBRANES 2021; 11:535. [PMID: 34357186 PMCID: PMC8303522 DOI: 10.3390/membranes11070535] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/19/2021] [Revised: 07/06/2021] [Accepted: 07/12/2021] [Indexed: 11/16/2022]
Abstract
Manipulation of ions and molecules by external control at the nanoscale is highly relevant to biomedical applications. We report a biocompatible electrode-embedded nanofluidic channel membrane designed for electrofluidic applications such as ionic field-effect transistors for implantable drug-delivery systems. Our nanofluidic membrane includes a polysilicon electrode electrically isolated by amorphous silicon carbide (a-SiC). The nanochannel gating performance was experimentally investigated based on the current-voltage (I-V) characteristics, leakage current, and power consumption in potassium chloride (KCl) electrolyte. We observed significant modulation of ionic diffusive transport of both positively and negatively charged ions under physical confinement of nanochannels, with low power consumption. To study the physical mechanism associated with the gating performance, we performed electrochemical impedance spectroscopy. The results showed that the flat band voltage and density of states were significantly low. In light of its remarkable performance in terms of ionic modulation and low power consumption, this new biocompatible nanofluidic membrane could lead to a new class of silicon implantable nanofluidic systems for tunable drug delivery and personalized medicine.
Collapse
Affiliation(s)
- Antonia Silvestri
- Department of Electronics and Telecommunications, Polytechnic of Turin, 10129 Turin, Italy; (A.S.); (P.M.R.); (D.D.)
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; (N.D.T.); (Y.W.); (X.L.)
| | - Nicola Di Trani
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; (N.D.T.); (Y.W.); (X.L.)
| | - Giancarlo Canavese
- Department of Applied Science and Technology, Polytechnic of Turin, 10129 Turin, Italy; (G.C.); (L.I.); (S.G.)
| | - Paolo Motto Ros
- Department of Electronics and Telecommunications, Polytechnic of Turin, 10129 Turin, Italy; (A.S.); (P.M.R.); (D.D.)
| | - Leonardo Iannucci
- Department of Applied Science and Technology, Polytechnic of Turin, 10129 Turin, Italy; (G.C.); (L.I.); (S.G.)
| | - Sabrina Grassini
- Department of Applied Science and Technology, Polytechnic of Turin, 10129 Turin, Italy; (G.C.); (L.I.); (S.G.)
| | - Yu Wang
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; (N.D.T.); (Y.W.); (X.L.)
| | - Xuewu Liu
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; (N.D.T.); (Y.W.); (X.L.)
| | - Danilo Demarchi
- Department of Electronics and Telecommunications, Polytechnic of Turin, 10129 Turin, Italy; (A.S.); (P.M.R.); (D.D.)
| | - Alessandro Grattoni
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; (N.D.T.); (Y.W.); (X.L.)
- Department of Surgery, Houston Methodist Research Institute, Houston, TX 77030, USA
- Department of Radiation Oncology, Houston Methodist Research Institute, Houston, TX 77030, USA
| |
Collapse
|
7
|
Di Trani N, Silvestri A, Sizovs A, Wang Y, Erm DR, Demarchi D, Liu X, Grattoni A. Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery. LAB ON A CHIP 2020; 20:1562-1576. [PMID: 32249279 PMCID: PMC7249613 DOI: 10.1039/d0lc00121j] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
Patient-centered therapeutic management for chronic medical conditions is a desired but unmet need, largely attributable to the lack of adequate technologies for tailored drug administration. While triggered devices that control the delivery of therapeutics exist, they often rely on impractical continuous external activation. As such, next generation continuously tunable drug delivery systems independent of sustained external activation remain an elusive goal. Here we present the development and demonstration of a silicon carbide (SiC)-coated nanofluidic membrane that achieves reproducible and tunable control of drug release via electrostatic gating. By applying a low-intensity voltage to a buried electrode, we showed repeatable and reproducible in vitro release modulation of three model analytes. A small fluorophore (Alexa Fluor 647), a large polymer poly(sodium 4-styrenesulfonate) and a medically relevant agent (DNA), were selected as representatives of small molecule therapeutics, polymeric drug carriers, and biological therapeutics, respectively. Unlike other drug delivery systems, our technology performed consistently over numerous cycles of voltage modulation, for over 11 days. Importantly, low power consumption and minimal leakage currents were achieved during the study. Further, the SiC coating maintained integrity and chemical inertness, shielding the membrane from degradation under simulated physiological and accelerated conditions for over 4 months. Through leveraging the flexibility offered by electrostatic gating control, our technology provides a valuable strategy for tunable delivery, setting the foundation for the next generation of drug delivery systems.
Collapse
Affiliation(s)
- Nicola Di Trani
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA. and University of Chinese Academy of Science (UCAS), Shijingshan, 19 Yuquan Road, Beijing 100049, China
| | - Antonia Silvestri
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA. and Department of Electronics and Telecommunications, Polytechnic of Turin, Turin, Italy
| | - Antons Sizovs
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA.
| | - Yu Wang
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA.
| | - Donald R Erm
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA.
| | - Danilo Demarchi
- Department of Electronics and Telecommunications, Polytechnic of Turin, Turin, Italy
| | - Xuewu Liu
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA.
| | - Alessandro Grattoni
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA. and Department of Surgery, Houston Methodist Hospital, Houston, TX, USA and Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, USA
| |
Collapse
|
8
|
Di Trani N, Silvestri A, Bruno G, Geninatti T, Chua CYX, Gilbert A, Rizzo G, Filgueira CS, Demarchi D, Grattoni A. Remotely controlled nanofluidic implantable platform for tunable drug delivery. LAB ON A CHIP 2019; 19:2192-2204. [PMID: 31169840 DOI: 10.1039/c9lc00394k] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/19/2023]
Abstract
Chronic diseases such as hypertension and rheumatoid arthritis are persistent ailments that require personalized lifelong therapeutic management. However, the difficulty of adherence to strict dosing schedule compromises therapeutic efficacy and safety. Moreover, the conventional one-size-fits-all treatment approach is increasingly challenged due to the intricacies of inter- and intra-individual variabilities. While accelerated technological advances have led to sophisticated implantable drug delivery devices, flexibility in dosage and timing modulation to tailor precise treatment to individual needs remains an elusive goal. Here we describe the development of a subcutaneously implantable remote-controlled nanofluidic device capable of sustained drug release with adjustable dosing and timing. By leveraging a low intensity electric field to modify the concentration driven diffusion across a nanofluidic membrane, the rate of drug administration can be increased, decreased or stopped via Bluetooth remote command. We demonstrate in vitro the release modulation of enalapril and methotrexate, first-line therapeutics for treatment of hypertension and rheumatoid arthritis, respectively. Further, we show reliable remote communication and device biocompatibility via in vivo studies. Unlike a pulsatile release regimen typical of some conventional controlled delivery systems, our implant offers a continuous drug administration that avoids abrupt fluctuations, which could affect response and tolerability. Our system could set the foundation for an on-demand delivery platform technology for long term management of chronic diseases.
Collapse
Affiliation(s)
- Nicola Di Trani
- Nanomedicine Department, Houston Methodist Research Institute, Houston, TX, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Pons-Faudoa FP, Ballerini A, Sakamoto J, Grattoni A. Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases. Biomed Microdevices 2019; 21:47. [PMID: 31104136 PMCID: PMC7161312 DOI: 10.1007/s10544-019-0389-6] [Citation(s) in RCA: 100] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Chronic diseases account for the majority of all deaths worldwide, and their prevalence is expected to escalate in the next 10 years. Because chronic disorders require long-term therapy, the healthcare system must address the needs of an increasing number of patients. The use of new drug administration routes, specifically implantable drug delivery devices, has the potential to reduce treatment-monitoring clinical visits and follow-ups with healthcare providers. Also, implantable drug delivery devices can be designed to maintain drug concentrations in the therapeutic window to achieve controlled, continuous release of therapeutics over extended periods, eliminating the risk of patient non-compliance to oral treatment. A higher local drug concentration can be achieved if the device is implanted in the affected tissue, reducing systemic adverse side effects and decreasing the challenges and discomfort of parenteral treatment. Although implantable drug delivery devices have existed for some time, interest in their therapeutic potential is growing, with a global market expected to reach over $12 billion USD by 2018. This review discusses implantable drug delivery technologies in an advanced stage of development or in clinical use and focuses on the state-of-the-art of reservoir-based implants including pumps, electromechanical systems, and polymers, sites of implantation and side effects, and deployment in developing countries.
Collapse
Affiliation(s)
- Fernanda P Pons-Faudoa
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX, 77030, USA
- School of Medicine and Health Sciences, Tecnologico de Monterrey, Avenida Eugenio Garza Sada 2501, 64849, Monterrey, NL, Mexico
| | - Andrea Ballerini
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX, 77030, USA
- Department of Oncology and Onco-Hematology, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy
| | - Jason Sakamoto
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX, 77030, USA
| | - Alessandro Grattoni
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX, 77030, USA.
- Department of Surgery, Houston Methodist Hospital, 6550 Fannin Street, Houston, TX, 77030, USA.
- Department of Radiation Oncology, Houston Methodist Hospital, 6550 Fannin Street, Houston, TX, 77030, USA.
| |
Collapse
|
10
|
Chakravarthy KV, Boehm FJ, Christo PJ. Nanotechnology: A Promising New Paradigm for the Control of Pain. PAIN MEDICINE 2019; 19:232-243. [PMID: 29036629 DOI: 10.1093/pm/pnx131] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Objective The objective of this article is to critically review both preclinical and clinical studies that focus on the use of nanotechnology for both acute and chronic pain management, surveying both diagnostic and therapeutic applications. The article also provides information on nanotechnology for pain practitioners, so that they may better understand how this technology works and how it may be applied to their day-to-day clinical practice. Study Design Narrative review. Methods The Pubmed NCBI and EMBASE databases were utilized to review published reports of in vivo and clinical studies that focus on using nanotechnology for pain management applications in both the acute and chronic pain settings. Results Articles were screened by title, abstract, and full article review. They were then analyzed by specific clinical indications, and appropriate data were presented based on a critical analysis of those articles. Conclusions As the development of nanomedical applications in acute and chronic pain management continues, medical practitioners should consider their growing potential to enhance the care of patients who are consistently living with pain. Current barriers to implementation include manufacturing scale-up for commercial viability, long-term nanoparticle toxicity considerations, and high cost for successful passage through clinical trials. These challenges will need to be overcome with ongoing translational research efforts in collaboration with industry and government bodies such as the Food and Drug Administration (FDA).
Collapse
Affiliation(s)
- Krishnan V Chakravarthy
- Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts.,Johns Hopkins Institute for NanoBioTechnology (INBT), Baltimore, Maryland
| | | | - Paul J Christo
- Department of Anesthesiology and Critical Care Medicine, Division of Pain Medicine, Johns Hopkins Hospital, Baltimore, Maryland, USA
| |
Collapse
|
11
|
Scorrano G, Bruno G, Trani ND, Ferrari M, Pimpinelli A, Grattoni A. Gas Flow at the Ultra-nanoscale: Universal Predictive Model and Validation in Nanochannels of Ångstrom-Level Resolution. ACS APPLIED MATERIALS & INTERFACES 2018; 10:32233-32238. [PMID: 30185043 PMCID: PMC6836450 DOI: 10.1021/acsami.8b11455] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/19/2023]
Abstract
Gas transport across nanoscale pores is determinant in molecular exchange in living organisms as well as in a broad spectrum of technologies. Here, we report an unprecedented theoretical and experimental analysis of gas transport in a consistent set of confining nanochannels ranging in size from the ultra-nanoscale to the sub-microscale. A generally applicable theoretical approach quantitatively predicting confined gas flow in the Knudsen and transition regime was developed. Unlike current theories, specifically designed for very simple channel geometries, our approach can be applied to virtually all geometries, for which the probability distribution of path lengths for particle-interface collisions can be computed, either analytically or by numerical simulations. To generate a much needed benchmark experimental model, we manufactured extremely reproducible membranes with two-dimensional nanochannels. Channel sizes ranged from 2.5 to 250 nm, and angstrom level of size control and interface tolerances were achieved using leading-edge nanofabrication techniques. We then measured gas flow in the Knudsen number range from 0.2 to 20. Excellent agreement between theoretical predictions and experimental data was found, demonstrating the validity and potential of our approach.
Collapse
Affiliation(s)
- Giovanni Scorrano
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas,77030, USA
- Department of Material Science and Nanoengineering, Rice University, Houston, Texas, 77005, USA
| | - Giacomo Bruno
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas,77030, USA
| | - Nicola Di Trani
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas,77030, USA
| | - Mauro Ferrari
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas,77030, USA
| | - Alberto Pimpinelli
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas,77030, USA
- Smalley-Curl Institute, Rice University, Houston, Texas, 77005, USA
| | - Alessandro Grattoni
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas,77030, USA
- Department of Surgery, Houston Methodist Hospital, Houston, Texas, 77030, USA
- Department of Radiation Oncology, Houston Methodist Hospital, Houston, Texas, 77030, USA
- corresponding author:
| |
Collapse
|
12
|
Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis. J Control Release 2018; 286:315-325. [PMID: 30092254 DOI: 10.1016/j.jconrel.2018.08.010] [Citation(s) in RCA: 61] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2018] [Revised: 06/20/2018] [Accepted: 08/03/2018] [Indexed: 02/07/2023]
Abstract
Pre-exposure prophylaxis (PrEP) with antiretroviral (ARV) drugs are effective at preventing human immunodeficiency virus (HIV) transmission. However, implementation of PrEP presents significant challenges due to poor user adherence, low accessibility to ARVs and multiple routes of HIV exposure. To address these challenges, we developed the nanochannel delivery implant (NDI), a subcutaneously implantable device for sustained and constant delivery of tenofovir alafenamide (TAF) and emtricitabine (FTC) for HIV PrEP. Unlike existing drug delivery platforms with finite depots, the NDI incorporates ports allowing for transcutaneous refilling upon drug exhaustion. NDI-mediated drug delivery in rhesus macaques resulted in sustained release of both TAF and FTC for 83 days, as indicated by concentrations of TAF, FTC and their respectively metabolites in plasma, PBMCs, rectal mononuclear cells and tissues associated with HIV transmission. Notably, clinically relevant preventative levels of tenofovir diphosphate were achieved as early as 3 days after NDI implantation. We also demonstrated the feasibility of transcutaneous drug refilling to extend the duration of PrEP drug delivery in NHPs. Overall, the NDI represents an innovative strategy for long-term HIV PrEP administration in both developed and developing countries.
Collapse
|
13
|
Adamo F, Farina M, Thekkedath UR, Grattoni A, Sesana R. Mechanical characterization and numerical simulation of a subcutaneous implantable 3D printed cell encapsulation system. J Mech Behav Biomed Mater 2018; 82:133-144. [DOI: 10.1016/j.jmbbm.2018.03.023] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2017] [Revised: 03/16/2018] [Accepted: 03/19/2018] [Indexed: 12/27/2022]
|
14
|
Transcutaneously refillable, 3D-printed biopolymeric encapsulation system for the transplantation of endocrine cells. Biomaterials 2018; 177:125-138. [PMID: 29886385 DOI: 10.1016/j.biomaterials.2018.05.047] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2018] [Revised: 05/17/2018] [Accepted: 05/27/2018] [Indexed: 12/17/2022]
Abstract
Autologous cell transplantation holds enormous promise to restore organ and tissue functions in the treatment of various pathologies including endocrine, cardiovascular, and neurological diseases among others. Even though immune rejection is circumvented with autologous transplantation, clinical adoption remains limited due to poor cell retention and survival. Cell transplant success requires homing to vascularized environment, cell engraftment and importantly, maintenance of inherent cell function. To address this need, we developed a three dimensional (3D) printed cell encapsulation device created with polylactic acid (PLA), termed neovascularized implantable cell homing and encapsulation (NICHE). In this paper, we present the development and systematic evaluation of the NICHE in vitro, and the in vivo validation with encapsulated testosterone-secreting Leydig cells in Rag1-/- castrated mice. Enhanced subcutaneous vascularization of NICHE via platelet-rich plasma (PRP) hydrogel coating and filling was demonstrated in vivo via a chorioallantoic membrane (CAM) assay as well as in mice. After establishment of a pre-vascularized bed within the NICHE, transcutaneously transplanted Leydig cells, maintained viability and robust testosterone secretion for the duration of the study. Immunohistochemical analysis revealed extensive Leydig cell colonization in the NICHE. Furthermore, transplanted cells achieved physiologic testosterone levels in castrated mice. The promising results provide a proof of concept for the NICHE as a viable platform technology for autologous cell transplantation for the treatment of a variety of diseases.
Collapse
|
15
|
Bruno G, Di Trani N, Hood RL, Zabre E, Filgueira CS, Canavese G, Jain P, Smith Z, Demarchi D, Hosali S, Pimpinelli A, Ferrari M, Grattoni A. Unexpected behaviors in molecular transport through size-controlled nanochannels down to the ultra-nanoscale. Nat Commun 2018; 9:1682. [PMID: 29703954 PMCID: PMC5923292 DOI: 10.1038/s41467-018-04133-8] [Citation(s) in RCA: 51] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2017] [Accepted: 04/06/2018] [Indexed: 12/26/2022] Open
Abstract
Ionic transport through nanofluidic systems is a problem of fundamental interest in transport physics and has broad relevance in desalination, fuel cells, batteries, filtration, and drug delivery. When the dimension of the fluidic system approaches the size of molecules in solution, fluid properties are not homogeneous and a departure in behavior is observed with respect to continuum-based theories. Here we present a systematic study of the transport of charged and neutral small molecules in an ideal nanofluidic platform with precise channels from the sub-microscale to the ultra-nanoscale (<5 nm). Surprisingly, we find that diffusive transport of nano-confined neutral molecules matches that of charged molecules, as though the former carry an effective charge. Further, approaching the ultra-nanoscale molecular diffusivities suddenly drop by up to an order of magnitude for all molecules, irrespective of their electric charge. New theoretical investigations will be required to shed light onto these intriguing results. Transport through nanochannels is usually dominated by electrostatic interactions and depends on the charge of diffusing molecules. Here the authors show that for channel heights between 2 and 4 nanometers, transport is insensitive to molecule charge.
Collapse
Affiliation(s)
- Giacomo Bruno
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA.,Department of Electronics and Telecommunications, Politecnico di Torino, 10024, Turin, Italy
| | - Nicola Di Trani
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA.,Department of Electronics and Telecommunications, Politecnico di Torino, 10024, Turin, Italy
| | - R Lyle Hood
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA
| | - Erika Zabre
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA
| | - Carly Sue Filgueira
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA
| | - Giancarlo Canavese
- Department of Applied Science and Technology, Politecnico di Torino, 10024, Turin, Italy
| | - Priya Jain
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA
| | - Zachary Smith
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA
| | - Danilo Demarchi
- Department of Electronics and Telecommunications, Politecnico di Torino, 10024, Turin, Italy
| | | | - Alberto Pimpinelli
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA.,Smalley-Curl Institute, Rice University, Houston, TX, 77005, USA.,Department of Material Science and Nanoengineering, Rice University, Houston, Texas, 77005, USA
| | - Mauro Ferrari
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA
| | - Alessandro Grattoni
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA.
| |
Collapse
|
16
|
Abstract
Transplantation is often the only choice many patients have when suffering from end-stage organ failure. Although the quality of life improves after transplantation, challenges, such as organ shortages, necessary immunosuppression with associated complications, and chronic graft rejection, limit its wide clinical application. Nanotechnology has emerged in the past 2 decades as a field with the potential to satisfy clinical needs in the area of targeted and sustained drug delivery, noninvasive imaging, and tissue engineering. In this article, we provide an overview of popular nanotechnologies and a summary of the current and potential uses of nanotechnology in cell and organ transplantation.
Collapse
|
17
|
Hood RL, Hood GD, Ferrari M, Grattoni A. Pioneering medical advances through nanofluidic implantable technologies. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY 2017; 9. [DOI: 10.1002/wnan.1455] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/08/2016] [Revised: 11/27/2016] [Accepted: 12/17/2016] [Indexed: 12/11/2022]
Affiliation(s)
- R. Lyle Hood
- Department of Nanomedicine; Houston Methodist Research Institute; Houston TX USA
- Department of Mechanical Engineering; University of Texas San Antonio; San Antonio TX USA
| | - Gold Darr Hood
- Department of Nanomedicine; Houston Methodist Research Institute; Houston TX USA
| | - Mauro Ferrari
- Department of Nanomedicine; Houston Methodist Research Institute; Houston TX USA
| | - Alessandro Grattoni
- Department of Nanomedicine; Houston Methodist Research Institute; Houston TX USA
| |
Collapse
|
18
|
Bruno G, Canavese G, Liu X, Filgueira CS, Sacco A, Demarchi D, Ferrari M, Grattoni A. The active modulation of drug release by an ionic field effect transistor for an ultra-low power implantable nanofluidic system. NANOSCALE 2016; 8:18718-18725. [PMID: 27787528 PMCID: PMC5166607 DOI: 10.1039/c6nr06235k] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
We report an electro-nanofluidic membrane for tunable, ultra-low power drug delivery employing an ionic field effect transistor. Therapeutic release from a drug reservoir was successfully modulated, with high energy efficiency, by actively adjusting the surface charge of slit-nanochannels 50, 110, and 160 nm in size, by the polarization of a buried gate electrode and the consequent variation of the electrical double layer in the nanochannel. We demonstrated control over the transport of ionic species, including two relevant hypertension drugs, atenolol and perindopril, that could benefit from such modulation. By leveraging concentration-driven diffusion, we achieve a 2 to 3 order of magnitude reduction in power consumption as compared to other electrokinetic phenomena. The application of a small gate potential (±5 V) in close proximity (150 nm) of 50 nm nanochannels generated a sufficiently strong electric field, which doubled or blocked the ionic flux depending on the polarity of the voltage applied. These compelling findings can lead to next generation, more reliable, smaller, and longer lasting drug delivery implants with ultra-low power consumption.
Collapse
Affiliation(s)
- Giacomo Bruno
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX 77030, USA. and Department of Electronics and Telecommunications, Politecnico di Torino, Corso Duca degli Abruzzi 24, Turin 10129, Italy
| | - Giancarlo Canavese
- Department of Applied Sciences and Technology, Politecnico di Torino, Corso Duca degli Abruzzi 24, Turin 10129, Italy
| | - Xuewu Liu
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX 77030, USA.
| | - Carly S Filgueira
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX 77030, USA.
| | - Adriano Sacco
- Center for Sustainable Futures @POLITO, Instituto Italiano di Tecnologia, Corso Trento 21, Turin 10129, Italy
| | - Danilo Demarchi
- Department of Electronics and Telecommunications, Politecnico di Torino, Corso Duca degli Abruzzi 24, Turin 10129, Italy
| | - Mauro Ferrari
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX 77030, USA.
| | - Alessandro Grattoni
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX 77030, USA.
| |
Collapse
|
19
|
Geninatti T, Hood RL, Bruno G, Jain P, Nicolov E, Ziemys A, Grattoni A. Sustained Administration of Hormones Exploiting Nanoconfined Diffusion through Nanochannel Membranes. MATERIALS 2015; 8:5276-5288. [PMID: 27293533 PMCID: PMC4898476 DOI: 10.3390/ma8085241] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Implantable devices may provide a superior means for hormone delivery through maintaining serum levels within target therapeutic windows. Zero-order administration has been shown to reach an equilibrium with metabolic clearance, resulting in a constant serum concentration and bioavailability of released hormones. By exploiting surface-to-molecule interaction within nanochannel membranes, it is possible to achieve a long-term, constant diffusive release of agents from implantable reservoirs. In this study, we sought to demonstrate the controlled release of model hormones from a novel nanochannel system. We investigated the delivery of hormones through our nanochannel membrane over a period of 40 days. Levothyroxine, osteocalcin and testosterone were selected as representative hormones based on their different molecular properties and structures. The release mechanisms and transport behaviors of these hormones within 3, 5 and 40 nm channels were characterized. Results further supported the suitability of the nanochannels for sustained administration from implantable platforms.
Collapse
Affiliation(s)
- Thomas Geninatti
- Nanomedicine Department, Houston Methodist Research Institute, Houston, TX 77030, USA; E-Mails: (R.L.H.); (P.J.); (E.N.); (A.Z.)
- College of Materials Science and Engineering, University of Chinese Academy of Sciences, Beijing 100049, China; E-Mail:
| | - R. Lyle Hood
- Nanomedicine Department, Houston Methodist Research Institute, Houston, TX 77030, USA; E-Mails: (R.L.H.); (P.J.); (E.N.); (A.Z.)
| | - Giacomo Bruno
- Nanomedicine Department, Houston Methodist Research Institute, Houston, TX 77030, USA; E-Mails: (R.L.H.); (P.J.); (E.N.); (A.Z.)
- Electronics and Telecommunications Department, Politecnico di Torino, Turin 10024, Italy; E-Mail:
| | - Priya Jain
- Nanomedicine Department, Houston Methodist Research Institute, Houston, TX 77030, USA; E-Mails: (R.L.H.); (P.J.); (E.N.); (A.Z.)
| | - Eugenia Nicolov
- Nanomedicine Department, Houston Methodist Research Institute, Houston, TX 77030, USA; E-Mails: (R.L.H.); (P.J.); (E.N.); (A.Z.)
| | - Arturas Ziemys
- Nanomedicine Department, Houston Methodist Research Institute, Houston, TX 77030, USA; E-Mails: (R.L.H.); (P.J.); (E.N.); (A.Z.)
| | - Alessandro Grattoni
- Nanomedicine Department, Houston Methodist Research Institute, Houston, TX 77030, USA; E-Mails: (R.L.H.); (P.J.); (E.N.); (A.Z.)
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +1-713-441-7324; Fax: +1-713-441-3655
| |
Collapse
|
20
|
Ferrati S, Nicolov E, Zabre E, Geninatti T, Shirkey BA, Hudson L, Hosali S, Crawley M, Khera M, Palapattu G, Grattoni A. The Nanochannel Delivery System for Constant Testosterone Replacement Therapy. J Sex Med 2015; 12:1375-80. [DOI: 10.1111/jsm.12897] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|